Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Sex Ratio | 1 | 2021 | 69 | 0.85 | Why? |
| Nevirapine | 1 | 2018 | 57 | 0.75 | Why? |
| Anti-HIV Agents | 4 | 2019 | 2209 | 0.75 | Why? |
| Medical History Taking | 1 | 2021 | 350 | 0.74 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.52 | Why? |
| HIV Infections | 8 | 2020 | 11620 | 0.42 | Why? |
| Hepatitis C | 1 | 2021 | 1514 | 0.38 | Why? |
| Dengue | 1 | 2021 | 1565 | 0.36 | Why? |
| Ritonavir | 3 | 2020 | 4212 | 0.33 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.32 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.30 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.27 | Why? |
| Italy | 16 | 2021 | 38444 | 0.27 | Why? |
| Polypharmacology | 1 | 2021 | 33 | 0.23 | Why? |
| Drug Interactions | 4 | 2021 | 1653 | 0.21 | Why? |
| Enterococcus | 1 | 2021 | 73 | 0.21 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.21 | Why? |
| Multiple Chronic Conditions | 1 | 2021 | 115 | 0.21 | Why? |
| Self Report | 3 | 2021 | 3802 | 0.20 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 1261 | 0.20 | Why? |
| Endothelial Progenitor Cells | 1 | 2020 | 103 | 0.19 | Why? |
| Prescriptions | 1 | 2020 | 258 | 0.19 | Why? |
| HIV Seronegativity | 1 | 2018 | 112 | 0.18 | Why? |
| Anti-Obesity Agents | 1 | 2018 | 52 | 0.18 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.18 | Why? |
| Nonprescription Drugs | 1 | 2018 | 78 | 0.17 | Why? |
| Mass Screening | 4 | 2021 | 8005 | 0.17 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.17 | Why? |
| Virus Replication | 1 | 2019 | 14331 | 0.17 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2021 | 323 | 0.16 | Why? |
| Virus Latency | 1 | 2019 | 251 | 0.16 | Why? |
| Cobicistat | 1 | 2018 | 172 | 0.16 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.16 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.16 | Why? |
| Fluorenes | 1 | 2016 | 101 | 0.15 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.14 | Why? |
| HIV | 2 | 2018 | 1116 | 0.14 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.13 | Why? |
| Benzimidazoles | 1 | 2016 | 275 | 0.13 | Why? |
| Dengue Virus | 1 | 2021 | 910 | 0.13 | Why? |
| Psychotropic Drugs | 1 | 2018 | 396 | 0.13 | Why? |
| Psychometrics | 1 | 2021 | 1269 | 0.13 | Why? |
| Drug Combinations | 2 | 2020 | 3852 | 0.13 | Why? |
| Patients | 1 | 2021 | 1167 | 0.12 | Why? |
| Communicable Diseases, Imported | 1 | 2021 | 843 | 0.12 | Why? |
| Appointments and Schedules | 1 | 2021 | 1204 | 0.12 | Why? |
| Health Surveys | 2 | 2021 | 2841 | 0.12 | Why? |
| Drug Prescriptions | 1 | 2020 | 1062 | 0.12 | Why? |
| Sofosbuvir | 1 | 2016 | 518 | 0.11 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.11 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.11 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.11 | Why? |
| Humans | 34 | 2021 | 930598 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.11 | Why? |
| Male | 20 | 2021 | 367725 | 0.10 | Why? |
| Alanine | 4 | 2021 | 5687 | 0.10 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.10 | Why? |
| Apoptosis | 1 | 2020 | 2335 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2019 | 1579 | 0.10 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.09 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.09 | Why? |
| Female | 19 | 2021 | 380317 | 0.09 | Why? |
| Aged | 13 | 2021 | 215776 | 0.09 | Why? |
| Smoking | 1 | 2021 | 3358 | 0.08 | Why? |
| Hepatitis C, Chronic | 1 | 2016 | 973 | 0.08 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.08 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.08 | Why? |
| Polypharmacy | 2 | 2020 | 347 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.08 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.07 | Why? |
| Drug Discovery | 1 | 2019 | 3092 | 0.07 | Why? |
| Cross-Sectional Studies | 6 | 2021 | 53120 | 0.07 | Why? |
| Influenza Vaccines | 1 | 2020 | 2941 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.07 | Why? |
| Adult | 12 | 2021 | 244371 | 0.07 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.06 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Travel | 1 | 2021 | 7220 | 0.06 | Why? |
| Pharmacokinetics | 1 | 2021 | 41 | 0.06 | Why? |
| CD146 Antigen | 1 | 2020 | 19 | 0.06 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Drug Antagonism | 1 | 2018 | 24 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Internet | 3 | 2021 | 6204 | 0.05 | Why? |
| Antipyretics | 1 | 2018 | 107 | 0.04 | Why? |
| Raltegravir Potassium | 1 | 2018 | 132 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.04 | Why? |
| Preliminary Data | 1 | 2018 | 457 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.04 | Why? |
| Quinolones | 1 | 2018 | 167 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.04 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.04 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.04 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.04 | Why? |
| Calcium Channel Blockers | 1 | 2018 | 367 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2021 | 43792 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Antidepressive Agents | 1 | 2018 | 509 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Health Care Costs | 1 | 2020 | 1007 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2019 | 25288 | 0.03 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.03 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.02 | Why? |
| Animals | 1 | 2019 | 78931 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2016 | 1158 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Family | 1 | 2021 | 2909 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Fear | 1 | 2021 | 3607 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| France | 1 | 2020 | 12074 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.02 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.01 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.01 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.01 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |